OSI Systems, Inc. (OSIS) - Q3 Fiscal 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for OSI Systems, Inc. for the quarter ended March 31, 2026 (Q3 Fiscal 2026). OSI is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in homeland security, healthcare, defense, and aerospace. The company operates through three primary divisions: Security, Optoelectronics and Manufacturing, and Healthcare.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD Q3 2026 (9 Months) | YTD Q3 2025 (9 Months) |
|---|---|---|---|---|
| Net Revenues | $453.2 million | $444.4 million | $1,301.9 million | $1,208.2 million |
| Gross Profit | $150.3 million | $150.3 million | $425.1 million | $418.9 million |
| Gross Margin | 33.2% | 33.8% | 32.7% | 34.7% |
| Operating Income | $53.2 million | $56.2 million | $145.1 million | $144.5 million |
| Net Income | $40.2 million | $41.1 million | $99.5 million | $96.9 million |
| Diluted EPS | $2.33 | $2.40 | $5.71 | $5.67 |
| Cash & Equivalents | $345.2 million (as of March 31, 2026) | |||
| Long-Term Debt | $998.7 million (as of March 31, 2026) | |||
| Operating Cash Flow (YTD) | $93.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 2.0% in Q3 and 7.8% YTD compared to the prior year. The Security division drove growth with a 9.5% YTD increase, while the Healthcare division declined 6.1% YTD due to lower patient monitoring sales.
- Margin Compression: Gross margins decreased slightly (33.8% to 33.2% in Q3; 34.7% to 32.7% YTD) primarily due to a less favorable product mix in the Security division compared to the prior year.
- Restructuring Charges: Impairment, restructuring, and other charges increased significantly to $6.2 million in Q3 (up from $2.3 million) and $11.8 million YTD (up from $3.6 million). This included $1.1 million for a legal settlement in the Healthcare division and $2.0 million in acquisition-related costs.
- Debt Structure: In November 2025, the company issued $575.0 million of 0.50% Convertible Senior Notes due 2031. Proceeds were used to repay $288.1 million of the revolving credit facility and repurchase $146.1 million of common stock. As of March 31, 2026, there were no borrowings outstanding under the revolving credit facility.
- Interest Expense: Net interest expense decreased to $4.0 million in Q3 (from $8.2 million) due to lower average interest rates following the debt refinancing and higher interest income on increased cash balances.
Outlook, Risks, and Management Commentary
- Guidance: The filing does not contain specific numerical guidance for the full fiscal year 2026. Management states that results for the interim periods are not necessarily indicative of future results.
- Market Risks: Management highlights exposure to global economic uncertainty, including the Russia-Ukraine conflict and Middle East tensions, which may disrupt supply chains and impact government spending. Tariffs and trade restrictions remain a concern.
- Supply Chain: The company notes tighter supply conditions and increased costs for memory and semiconductor components, driven by global demand for data center and AI infrastructure.
- Convertible Notes: The 2.25% Convertible Senior Notes due 2029 became eligible for conversion by holders during the quarter as the stock price exceeded 130% of the conversion price. The company has sufficient credit facility availability to settle these obligations if converted.
- Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, which includes changes to R&D capitalization and bonus depreciation.
Investor Verification Checklist
- Convertible Note Conversion Risk: Verify the current stock price relative to the $191.98 conversion price of the 2029 Notes to assess potential dilution or cash settlement requirements.
- Healthcare Segment Trends: Monitor the Healthcare division's performance, specifically the decline in patient monitoring sales, to determine if this is a temporary market fluctuation or a structural shift.
- Restructuring Execution: Track the cash outflow associated with the $11.8 million in YTD restructuring charges to ensure they align with the expected operational efficiency gains.
- Customer Concentration: Note that one customer in the Security division accounted for 40% of accounts receivable as of March 31, 2026, representing a significant concentration risk.
- Foreign Cash Repatriation: Approximately 25% of cash ($86.3 million) is held by foreign subsidiaries and subject to repatriation tax considerations; verify the company's strategy for utilizing these funds.